OT PlatformOT GeneticsCommunityBlog

Release notes

Summary of release highlights for the Open Targets Platform

24.09

Release date

18 September 2024

Highlights

New features

  • Users now have the ability to apply target-specific or disease/phenotype-specific filters to the target-disease association and target prioritisation pages. Read more details about the feature in our documentation.

Data updates

  • New safety liabilities associated with several targets which are routinely used by pharmaceutical companies have been added, from Brennan et al. (2024).

  • New Gene Burden evidence from the LoF burden analyses in FinnGen’s latest public release (R11).

  • New data from Reactome, Europe PMC, COSMIC and EVA (through ClinVar).

Product features

  • Improved visualisation for Gene essentiality data from Cancer DepMap.

  • Updated frontend table design and functionality leading to better searching/filtering and sorting functionality for most tables in the UI.

  • The classic associations view has been deprecated from the Platform..

Product enhancements and bug fixes

  • OpenAI model in the literature summarisation tool was updated to GPT-4o-mini.

  • Changes to variant field in the cancer biomarker evidence.

  • Aggregated the granularity of the description of phenotypes inside cohortPhenotypes to resolve duplication in ChEMBL evidence.

  • Bug fixes: pharmacogenetics schema, molecule dataset.

Check out the 24.09 release blog post for more information on the new features and datasets introduced in this release.

Overall data metrics

  • 63,121 targets

  • 28,327 diseases and phenotypes

  • 18,041 drugs and compounds

  • 17,853,184 evidence strings

  • 8,155,988 target-disease associations

Visit the Open Targets Community 24.09 release thread for more data metrics for this release, including a per datasource breakdown of evidence strings.

24.06

Release date

19 June 2024

Highlights

New features

  • Uploading a custom list of targets or diseases to obtain a tailored associations view allowing users to view selected target-disease evidence for the specific entities.

Data updates

  • Integration of ChEMBL 34 which now contains data from the European Medicines Agency (EMA) increasing drug-indication coverage.

  • Updates to the clinical trials and tractability data.

  • Updating the gene burden results from AstraZeneca’s PheWAS portal version 5.

  • New gene burden evidence for schizophrenia from the SCHEMA consortium and ancestry-specific evidence for prostate cancer.

  • A new Gene2Phenotype panel with musculo-skeletal implications.

  • New data from Reactome, COSMIC and EVA (through ClinVar), Probes and Drugs and GEL PanelApp increasing our coverage of data.

Product features

  • Ability to handle pharmacogenetic evidence involving drug combinations.

Product enhancements and bug fixes

  • Exclusion of splice QTLs from the assessment for the direction of effect and selecting the beta from the evidence with the lowest p-value instead of the largest effect size.

  • Improvements in the AotF GQL Playground Component.

  • Dropping isHumanApplicable field from target safety.

  • Bug fixes to the ClinVar (somatic) widget loading state.

  • Resolving an error in phenotype mapping in GEL PanelApp, resolving incorrect tractability precedence and removing categorical burden tests from Genebass data based on community feedback.

Check out the 24.06 release blog post for more information on the new features and datasets introduced in this release.

Overall data metrics

  • 63,226 targets

  • 28,198 diseases and phenotypes

  • 18,041 drugs and compounds

  • 17,703,456 evidence strings

  • 8,079,215 target-disease associations

Visit the Open Targets Community 24.06 release thread for more data metrics for this release, including a per datasource breakdown of evidence strings.

24.03

Release date

20 March 2024

Highlights

New features

  • Implementation of direction of effect assessment for eight different sources of target-disease association evidence.

  • Filtering bibliography data based on a publication date.

Data updates

  • Integration of the latest dataset from Project Score.

  • Integration of the 23Q4 version of DepMap (depmap.org).

  • New data from Reactome, COSMIC and EVA (through ClinVar) increasing our coverage of data.

Product features

  • Inclusion of star alleles from PharmGKB and a new Direct Drug Target column to the pharmacogenetics widget.

  • Use of pharmacogenetics data to inform adverse drug response as an additional source of information on target safety.

  • New dedicated GraphQL API query playground for Associations-on-the-Fly and target prioritisation view.

Product enhancements and bug fixes

  • Redesigned context menu with a new navigation and pinning behaviour.

  • Updated protvista-uniprot viewer library to v2.11.1.

  • Bug fixes to download file schema and search issues.

Check out the 24.03 release blog post for more information on the new features and datasets introduced in this release.

Overall data metrics

  • 63,226 targets

  • 25,817 diseases and phenotypes

  • 17,111 drugs and compounds

  • 17,317,290 evidence strings

  • 7,802,260 target-disease associations

Visit the Open Targets Community 24.03 release thread for more data metrics for this release, including a per datasource breakdown of evidence strings.

23.12

Release date

30 November 2023

Highlights

New features

  • 'Target Prioritisation' view: A new view for assessment of the target features considered when prioritising (or deprioritising) targets for drug discovery. Watch a detailed video here.

  • A new widget in the Platform adding pharmacogenetics data from PharmGKB.

Data updates

  • New data available on Baseline RNA and protein expression data for targets via the API and FTP.

  • New data from Reactome and EVA (through ClinVar) increasing our coverage of data.

Product features

  • Users can easily export the entire associations table and the target prioritisation table in json or tsv format.

  • Updated search bar design with search suggestions.

Product enhancements and bug fixes

  • Transition to OpenSearch from Elasticsearch.

  • Bug fixes in the widgets in the Association On The Fly view and styling issues.

Check out the 23.12 release blog post for more information on the new features and datasets introduced in this release.

Overall data metrics

  • 62,733 targets

  • 25,246 diseases and phenotypes

  • 17,095 drugs and compounds

  • 16,710,896 evidence strings

  • 7,994,180 target-disease associations

Visit the Open Targets Community 23.12 release thread for more data metrics for this release, including a per datasource breakdown of evidence strings.

23.09

Release date

21 September 2023

Highlights

New features

  • ‘Associations on the Fly’ - revamp of the current Open Targets Platform association page with new facets and additional built-in functionalities like view data directly in the associations table, control weights of contributing evidence, filter by datasource and data type (OR filters) and pin rows. Watch a detailed video here.

  • OpenAI Literature Summarisation tool - For data features that link to publications, users can ask for a natural language summary of the target-disease evidence presented in the publication using LangChain and OpenAI’s GPT3.5 Turbo model.

Data updates

  • Updated Molecular Interactions data source STRING Database to version 12.0

  • Increase in Europe PMC literature evidence by 9.9% to 10,355,423

  • New data from ChEMBL, COSMIC and EVA (through ClinVar) increasing our coverage of data

Product features

  • Easy access to the schema of the files available for download in the Open Targets Platform

Product enhancements and bug fixes

  • Expanded the definition of a drug to include all probes as reported by Probes & Drugs Portal (P&D) as chemical probes are useful from a target's doability perspective

  • Open Targets Platform user interface migration to Material UI v5

  • Refactoring of the sections in the frontend codebase - Components and sections moved into the packages/sections and packages/ui

Check out the 23.09 release blog post for more information on the new features and datasets introduced in this release.

Overall data metrics

  • 62,733 targets

  • 25,209 diseases and phenotypes

  • 17,096 drugs and compounds

  • 16,232,046 evidence strings

  • 7,922,844 target-disease associations

Visit the Open Targets Community 23.09 release thread for more data metrics for this release, including a per datasource breakdown of evidence strings.

23.06

Release date

26 June 2023

Highlights

New features

  • Addition of a CRISPR Screens widget featuring data from CRISPRBrain

  • Introduction of a Cancer DepMap widget showcasing gene essentiality data from the Cancer DepMap Portal

Data updates

  • Updated data from ChEMBL, including adverse event drug warning data and more granular information on clinical phases

  • New data from IntoGEN, Europe PMC, and EVA (through ClinVar) increasing our coverage of data

Product features

  • Missense variants in the OT Genetics, UniProt variants and ClinVar widgets now link to ProtVar, a new tool to interpret the functional consequences of human missense variants

Product enhancements and bug fixes

  • Fixes - homology widget, fixes to the data

  • More meaningful 404 error message

  • Fixed bugs in the API Playground

Check out the 23.06 release blog post for more information on the new features and datasets introduced in this release.

Overall data metrics

  • 62,685 targets

  • 24,713 diseases and phenotypes

  • 13,210 drugs and compounds

  • 15,117,741 evidence strings

  • 7,835,247 target-disease associations

Visit the Open Targets Community 23.06 release thread for more data metrics for this release, including a per datasource breakdown of evidence strings.

23.02

Release date

22 February 2023

Highlights

In addition to regular updates from our data providers, we have a number of new features in this release:

New evidence for target-disease associations

  • Additional data for metabolic biomarkers added to our Gene Burden widget

  • QTL-based direction of effect included in evidence from Open Targets Genetics

Improved target annotation data

  • Integration of Target safety evidence from AOPWiki

  • New data from Probes and Drugs’ 04.2022 release

Literature updates

  • Preprints and patents now included in our bibliography

Development updates

  • Redesigned search

  • Provenance metadata

Check out the 23.02 release blog post for more information on the new features and datasets introduced in this release.

Overall data metrics

  • 62,678 targets

  • 24,713 diseases and phenotypes

  • 12,854 drugs and compounds

  • 10,446,771 evidence strings

  • 6,656,559 target-disease associations

Visit the Open Targets Community 23.02 release thread for more data metrics for this release, including a per datasource breakdown of evidence strings.

22.11

Release date

24 November 2022

Highlights

In addition to continuous updates from our data providers, we have introduced the following new features:

  • Gene burden data for Parkinson’s disease

  • Updated classifications for clinical trial stop reasons

  • Variant functional consequences, available to browse in the Gene2Phenotype and Orphanet widgets

  • Other improvements and bug fixes

Check out the 22.11 release blog post for more information on the new features and datasets introduced in this release.

Overall data metrics

  • 62,678 targets

  • 22,274 diseases and phenotypes

  • 12,854 drugs and compounds

  • 14,611,717 evidence strings

  • 6,960,486 target-disease associations

Visit the Open Targets Community 22.11 release thread for more data metrics for this release, including a per datasource breakdown of evidence strings.

22.09

Release date

29 September 2022

Highlights

New data, in particular:

  • Open Targets Genetics

  • Genomics England PanelApp

  • Gene burden

  • Probes and drugs

  • New data integrity file, in line with FAIR principles

Check out the 22.09 release blog post for more information on the new features and datasets introduced in this release.

Overall data metrics

  • 61,888 targets

  • 20,931 diseases and phenotypes

  • 12,854 drugs and compounds

  • 14,229,684 evidence strings

  • 7,003,171 target-disease associations

Visit the Open Targets Community 22.09 release thread for more data metrics for this release, including a per datasource breakdown of evidence strings.

22.06

Release date

24 June 2022

Highlights

  • New data: five additional gene burden analyses from Genebass

  • New feature: new visualisation of subcellular locations of targets now available to users

  • New ontology term: “medical procedure”

Check out the 22.06 release blog post for more information on the new features and datasets introduced in this release.

Overall data metrics

  • 61,524 targets

  • 23,074 diseases and phenotypes

  • 12,854 drugs and compounds

  • 14,455,104 evidence strings

  • 7,247,865 target-disease associations

Visit the Open Targets Community 22.06 release thread for more data metrics for this release, including a per datasource breakdown of evidence strings.

22.04

Release date

28 April 2022

Highlights

  • New datasource: gene burden analyses from Regeneron and the AstraZeneca

  • Integration of structural variants from ClinVar

  • Additional information from DailyMed drug label text-mining

  • NLP classification of why clinical trials stopped

  • New data: Gene2phenotype cardiac panel

Check out the 22.04 release blog post for more information on the new features and datasets introduced in this release.

Overall data metrics

  • 61,524 targets

  • 18,520 diseases and phenotypes

  • 12,854 drugs and compounds

  • 13,829,174 evidence strings

  • 7,541,360 target-disease associations

Visit the Open Targets Community 22.04 release thread for more data metrics for this release, including a per datasource breakdown of evidence strings.

22.02

Release date

28 February 2022

Highlights

  • Gene2Phenotype terminology updated in line with the Gene Curation Coalition (GenCC)

  • Data updates from a range of providers including Open Targets Genetics and ChEMBL

Check out the 22.02 release blog post for more information on the new features and datasets introduced in this release.

Overall data metrics

  • 61,524 targets

  • 18,468 diseases and phenotypes

  • 12,594 drugs and compounds

  • 10,880,832 evidence strings

  • 7,980,448 target-disease associations

Visit the Open Targets Community 22.02 release thread for more data metrics for this release, including a per datasource breakdown of evidence strings.

21.11

Release date

29 November 2021

Highlights

  • New Cancer Biomarkers evidence data from the Cancer Genome Interpreter

  • Updated genetic association evidence from Open Targets Genetics

  • Embedded GraphQL API playground for each data table and query

Check out the 21.11 release blog post for more information on the new features and datasets introduced in this release.

Overall data metrics

  • 60,636 targets

  • 18,706 diseases and phenotypes

  • 12,594 drugs and compounds

  • 10,481,189 evidence strings

  • 7,787,231 target-disease associations

Visit the Open Targets Community 21.11 release thread for more data metrics for this release, including a per datasource breakdown of evidence strings.

21.09

Release date

30 September 2021

Highlights

  • Integration of new PROTAC tractability data from Schneider et al. (2021)

  • Integration of Genetic Constraint data from gnomAD and new Chemical Probes data from Probes & Drugs database

  • Data updates from EFO, ChEMBL, and Mouse Genome Informatics

  • Other improvements and bug fixes

Check out our 21.09 release blog post for more information on the new features and datasets introduced in this release.

Overall data metrics

  • 60,636 targets

  • 18,663 diseases and phenotypes

  • 12,594 drugs and compounds

  • 11,071,233 evidence strings

  • 7,927,820 target-disease associations

Visit the Open Targets Community 21.09 release thread for more data metrics for this release, including a per datasource breakdown of evidence strings.

21.06

Release date

30 June 2021

Highlights

  • Updated Open Targets Genetics Portal evidence, which included the integration of FinnGen biobank data (R5) and new GWAS Catalog studies

  • Integration of gene-disease data from Orphanet

  • Improvements to the user interface (e.g. datatype chips on evidence page)

  • Bug fixes (e.g. users can download Known Drugs table, association scores in datasets match values returned by API)

Check out our 21.06 release blog post for more information on the new features and datasets introduced in this release.

Overall data metrics

  • 60,606 targets

  • 18,507 diseases and phenotypes

  • 13,185 drugs and compounds

  • 13,267,236 evidence strings

  • 9,216,710 target-disease associations

Visit the Open Targets Community for more data metrics for this release, including a per datasource breakdown of evidence strings.

Archive

For release notes for previous releases, check out the Open Targets Community News & Announcement section.

PreviousLicenceNextTerms of use

Last updated